Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 61
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 3001 | OAKWOOD LABORATORIES | 5 | 00% | 0 | 5 | 2022–2025 |
| 3002 | OBI PHARMA | 5 | 00% | 0 | 5 | 2023–2025 |
| 3003 | OBRIST TECHNOLOGIES | 5 | 00% | 0 | 5 | 2023–2025 |
| 3004 | OKI ELECTRIC INDUSTRY | 5 | 120% | 2 | 2 | 2022–2024 |
| 3005 | OMEGA | 5 | 480% | 0 | 1 | 2020–2023 |
| 3006 | ON CLOUDS | 5 | 00% | 0 | 5 | 2025–2026 |
| 3007 | OOKLA | 5 | 120% | 0 | 4 | 2022–2025 |
| 3008 | OREXO | 5 | 00% | 1 | 4 | 2022–2025 |
| 3009 | ORION MACHINERY | 5 | 120% | 0 | 4 | 2022–2024 |
| 3010 | OSE IMMUNOTHERAPEUTICS | 5 | 00% | 0 | 5 | 2022–2023 |
| 3011 | OUTOKUMPU | 5 | 240% | 0 | 3 | 2016–2025 |
| 3012 | OXFORD PHOTOVOLTAICS | 5 | 120% | 0 | 4 | 2022–2024 |
| 3013 | P E S TECHNOLOGIES | 5 | 00% | 1 | 4 | 2022–2025 |
| 3014 | PARKER HANNIFIN EMEA | 5 | 240% | 0 | 3 | 2022–2024 |
| 3015 | PAUL M LLER KG UNTERNEHMENSBETEILIGUNGEN | 5 | 00% | 0 | 5 | 2026–2026 |
| 3016 | PDS BIOTECHNOLOGY | 5 | 00% | 1 | 4 | 2024–2026 |
| 3017 | PEARSON EDUCATION | 5 | 120% | 1 | 3 | 2019–2023 |
| 3018 | PEPPERL FUCHS SE | 5 | 00% | 0 | 5 | 2024–2026 |
| 3019 | PERFECT DAY | 5 | 00% | 5 | 0 | 2022–2024 |
| 3020 | PERHA PHARMACEUTICALS | 5 | 00% | 0 | 5 | 2022–2025 |
| 3021 | PETMEDIX | 5 | 00% | 0 | 5 | 2024–2025 |
| 3022 | PHOENIX CONTACT DEVELOPMENT AND MANUFACTURING | 5 | 360% | 0 | 2 | 2022–2023 |
| 3023 | PHOENIX TAILINGS | 5 | 00% | 0 | 5 | 2023–2025 |
| 3024 | PIBOND | 5 | 00% | 0 | 5 | 2025–2026 |
| 3025 | PLANT BIOSCIENCE | 5 | 00% | 1 | 4 | 2022–2025 |
| 3026 | PLASMA TECHNOLOGIES | 5 | 240% | 0 | 3 | 2022–2024 |
| 3027 | PLIANT THERAPEUTICS | 5 | 00% | 4 | 1 | 2022–2023 |
| 3028 | POLYPLASTICS | 5 | 240% | 0 | 3 | 2022–2023 |
| 3029 | POPSOCKETS | 5 | 00% | 1 | 4 | 2023–2023 |
| 3030 | POSEIDA THERAPEUTICS | 5 | 00% | 0 | 5 | 2022–2024 |
| 3031 | PRAMAND | 5 | 00% | 0 | 5 | 2023–2025 |
| 3032 | PRAYON | 5 | 00% | 0 | 5 | 2023–2026 |
| 3033 | PRC DESOTO INTERNATIONAL | 5 | 00% | 5 | 0 | 2022–2022 |
| 3034 | PREGIS | 5 | 00% | 0 | 5 | 2025–2025 |
| 3035 | PREVAIL THERAPEUTICS | 5 | 00% | 1 | 4 | 2023–2025 |
| 3036 | PROSPER TECHNOLOGIES | 5 | 00% | 0 | 5 | 2023–2025 |
| 3037 | PROTIX | 5 | 00% | 3 | 2 | 2022–2023 |
| 3038 | PSA AUTOMOBILES | 5 | 00% | 0 | 5 | 2022–2023 |
| 3039 | PX ING | 5 | 00% | 5 | 0 | 2023–2024 |
| 3040 | Q CUE | 5 | 120% | 0 | 4 | 2024–2026 |
| 3041 | QUALCOMM AUTO | 5 | 00% | 0 | 5 | 2024–2025 |
| 3042 | QUALICAPS | 5 | 00% | 0 | 5 | 2023–2025 |
| 3043 | QUANTUMSCAPE BATTERY | 5 | 00% | 0 | 5 | 2022–2024 |
| 3044 | REACH SURGICAL | 5 | 00% | 0 | 5 | 2022–2025 |
| 3045 | REALTA LIFE SCIENCES | 5 | 00% | 0 | 5 | 2023–2023 |
| 3046 | REARDEN | 5 | 00% | 3 | 2 | 2022–2024 |
| 3047 | REDEFINE MEAT | 5 | 00% | 0 | 5 | 2022–2024 |
| 3048 | REISHAUER | 5 | 00% | 0 | 5 | 2022–2025 |
| 3049 | RELAY THERAPEUTICS | 5 | 00% | 1 | 4 | 2022–2024 |
| 3050 | RENEW HEALTH | 5 | 120% | 0 | 4 | 2022–2024 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →